Biography
After completing his studies in pharmacy at the University of Alberta, Dr. Imran Khan undertook a pharmacy residency at the Foothills Medical Center in Calgary (2012) as well as a specialization certificate in pharmacotherapy (BCPS). He has worked at Hôpital Montfort for several years as a clinical pharmacist, mainly in the intensive care unit. He is actively involved in teaching both pharmacy and medical residents. He recently launched a project of clinical informatics to help implement computerized physician order entry (CPOE) software into the hospital and worked as a consultant for ambulatory software implementation. He is currently completing his PharmD degree at the Memorial University.
Expertise
- Pharmacotherapy
- Critical Care Medicine
- Clinical Informatics
- Professional Practice
- Clinical Research
Research Projects
Dr. Khan is particularly interested in the integration of new practices, the evaluation of drug use and pharmaco-economics. His pharmaco-economic research is aimed at proper stewardship and cost-saving workflows for HIV medication prescribing and utilization. The findings from the original research projects lead to significant cost-savings for the hospital.
Dr. Khan’s current research focuses on medications used in diabetes management and in particular the impact of sodium glucose transport inhibitors (SGLT2i) and the prevention of metabolic complications in the intensive care unit.
Publications
- Khan I, Kovacs B, Elias S, Dann M, Richler C, et al. Severe fulminant hypoxemic respiratory failure secondary to Mycoplasma pneumoniae in a previously healthy adult patient: A case report. Austin Crit Care Case Rep. 2025;10(1):1053.
- Khan I, Kwong A, Richler C, Landry C, Morin S, Thabet P. Diabetic ketoacidosis complicated by hypertriglyceridemia-induced pancreatitis: A case report. Case Rep Clin Med. 2024;13:587-596.
- Khan I, Kovacs B, Bédard D, Landry C, Richler C, et al. Case report: Prolonged ketoacidosis in sodium-glucose transport-2 inhibitor (SGLT2i) user. Austin Crit Care Case Rep. 2024;9(1):1052.
- Khan I, Kovacs B, Mercier S, Thabet P. Comparison of duration of ketoacidosis in sodium-glucose transport-2 inhibitor (SGLT2i) users and non-users among individuals with type 2 diabetes: Case series. Clin Case Rep Int. 2024;8:1687.
- Khan I, Kovacs B, Mercier S, Thabet P. Comparaison de la durée de la cétoacidose chez les utilisateurs et non-utilisateurs d'inhibiteurs du transporteur sodium-glucose de type 2 (SGLT2i) parmi les individus atteints de diabète de type 2 : Série de cas. Clin Case Rep Int. 2024 ; 8 : 1687.
- Khan I, Kovacs B, Bédard D, Landry C, Richler C, et al. Rapport de cas : Cétoacidose prolongée chez un utilisateur d'inhibiteurs du transporteur sodium-glucose de type 2 (SGLT2i). Austin Crit Care Case Rep. 2024 ; 9(1) : 1052.